Your session is about to expire
← Back to Search
Copanlisib for Chronic Lymphocytic Leukemia
Study Summary
This trial is studying the effects of adding copanlisib to ibrutinib or acalabrutinib in people with CLL that has returned or does not respond to treatment.
- Chronic Lymphocytic Leukemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 24 Patients • NCT02631590Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How hazardous is the application of Copanlisib for medicinal purposes?
"Copanlisib was evaluated as a 2 on our safety scale due to the lack of efficacy data despite supporting evidence for its safety in Phase 2 trials."
Are there any vacancies for prospective volunteers in this experiment?
"According to information on clinicialtrials.gov, this research study is actively recruiting participants and has been since it was posted in February of 2021 with its latest update being November 15th 2022."
How many participants are currently taking part in this clinical experiment?
"Affirmative. According to the information hosted on clinicaltrials.gov, this medical trial is actively seeking volunteers and was initially posted on February 18th 2021. The study requires 30 patients from a single medical centre for participation."
What medical conditions is Copanlisib typically used to treat?
"Copanlisib is a therapeutic procedure used to treat lymphoma, follicular and mantle cell lymphomas (MCLs), as well as Waldenstrom macroglobulinemia."
Share this study with friends
Copy Link
Messenger